Synaptogenix, Inc. today announced that it has completed enrolling its target of 100 patients for its ongoing National Institutes of Health (“NIH”) sponsored Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer’s disease (“AD”). The Company expects to announce topline data from the study during the fourth quarter of…
eTurboNews greinar eru eingöngu fyrir áskrifendur. Áskrift er ÓKEYPIS.
Skrá inn Smelltu hér til að gerast áskrifandi ÓKEYPIS
Skrá inn Smelltu hér til að gerast áskrifandi ÓKEYPIS
HVAÐ Á AÐ TAKA ÚR ÞESSARI GREIN:
- today announced that it has completed enrolling its target of 100 patients for its ongoing National Institutes of Health (“NIH”) sponsored Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer’s disease (“AD”).
- The Company expects to announce topline data from the study during the fourth quarter of….
- Áskrift er ÓKEYPIS.
